Health House International Limited (ASX:HHI)


right-arrow Created with Sketch. 0 (0%)
MCAP $14.25M
Last trade 15.18pm 19/01/2022 20mins delayed

Latest Announcements

10/01/2022HHIHealth House International Limited
20/12/2021HHIHealth House International Limited
15/12/2021 Price SensitivePSHHIHealth House International Limited
14/12/2021HHIHealth House International Limited
07/12/2021HHIHealth House International Limited
07/12/2021 Price SensitivePSHHIHealth House International Limited
02/12/2021HHIHealth House International Limited
12/11/2021HHIHealth House International Limited

Company Overview

Health House International Limited is an Australia-based international distributor of medicinal cannabis. Its primary activities include operations in the pharmaceutical wholesale and distribution sectors. It has two operating subsidiaries: Health House Pharma Limited, an international pharmaceutical distribution business in the United Kingdom and Health House International Pty Limited, a medicinal cannabis distribution business in Australia. Th products distributed by the Company include iX Biopharma’s Xativa, which is formulated using WaferiX, which is patented sublingual delivery technology, and Zelira Therapeutics’ cannabinoid-based customized medicines, including HOPE1, HOPE2 and Zenivol oil blended with pharmaceutical-grade sunflower oil. It distributes Levin Health’s cannabinoid-based, chronic pain medicines, such as LEVIN CBD 100 and LEVIN Balance 10:12. It also distributes products of various companies, such as Satipharm, HAPA pharm, Ananda Hemp and Little Green Pharma.

HHI in the news

Health House International’s (HHI) subsidiary entered an agreement to be the preferred…
Health House International (HHI) is set to expand into Europe’s largest medicinal…
Freshly re-listed Health House International (HHI) reported a drop in cash inflows…
Health House International (HHI) has signed a non-exclusive distribution agreement with U.K.-based…

Search Previous Announcements